ORENCIA VERSUS ROACTEMRA BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS.

ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPEN-LABELED, SUPERIORITY TRIAL. - SUNSTAR

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-000947-41-FR

Enrollment

224

Registered

2017-06-21

Start date

2017-08-18

Completion date

Unknown

Last updated

2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adults patients suffering from rheumatoid arthritis and in adequate response to a first line of treatment with a TNF alpha inhibitor. MedDRA version: 20.0 Level: HLT Classification code 10039075 Term: Rheumatoid arthritis and associated conditions System Organ Class: 100000004870

Interventions

Trade Name: ORENCIA 125 mg, solution injectable en seringue préremplie Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe Trade Name: RoActemra 162 mg solution injectable en s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - age >18 years - RA according to the ACR/EULAR 2010 criteria - inadequate response to a subcutaneously administered first-line TNFi defined as moderate to high disease activity (DAS28-ESR>3.2 and CDAI>10) after at least 3 months of treatment with a TNFi - beneficiary of the French National Health Insurance Fund - signed informed consent form - for women of childbearing age: effective contraception during treatment period with engagement to continue such contraception for 14 weeks after last administration Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 180 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 44

Exclusion criteria

Exclusion criteria: - counter-indication for one or other of the two drugs under study - Patient receiving a cortisteroid therapy over 15mg/day prednison equivalent for more than 4 weeks - failure of the TNFi for intolerance - breastfeeding woman

Design outcomes

Primary

Measure	Time frame
Main Objective: Compare tocilizumab versus abatacep administered subcutaneously efficacy in inadequate responder patients to a first-line biologic regimen with a TNFi.;Secondary Objective: 1/ Compare disease progression 2/ Compare treatments response and tolerance 3/ Evaluate radiobiological criteria to provide pathophysiological explanations to differential responses between drugs. ;Primary end point(s): Evolution of the Clinical Disease Activity Index (CDAI) at 6 months. The CDAI is a composite score combining clinical items only: Tender 28-joint count, Swollen 28-joint count, Patient Global Disease Activity (PGA), Evaluator’s Global Disease Activity (EGA). This score provides a numerical assessment reflecting disease activity independently of acute phase reactants. It is well known that acute phase reactants (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels) exhibit clear improvement with tocilizumab, better than with other treatments, but not necessarily with an associated clinical significance. ;Timepoint(s) of evaluation of this end point: At inlusion , 3, 6 and 12 months	—

Measure

Time frame

Main Objective: Compare tocilizumab versus abatacep administered subcutaneously efficacy in inadequate responder patients to a first-line biologic regimen with a TNFi.;Secondary Objective: 1/ Compare disease progression 2/ Compare treatments response and tolerance 3/ Evaluate radiobiological criteria to provide pathophysiological explanations to differential responses between drugs. ;Primary end point(s): Evolution of the Clinical Disease Activity Index (CDAI) at 6 months. The CDAI is a composite score combining clinical items only: Tender 28-joint count, Swollen 28-joint count, Patient Global Disease Activity (PGA), Evaluator’s Global Disease Activity (EGA). This score provides a numerical assessment reflecting disease activity independently of acute phase reactants. It is well known that acute phase reactants (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels) exhibit clear improvement with tocilizumab, better than with other treatments, but not necessarily with an associated clinical significance. ;Timepoint(s) of evaluation of this end point: At inlusion , 3, 6 and 12 months

—

Secondary

Measure	Time frame
Secondary end point(s): 1/ Secondary outcomes will assess treatment response. Comparisons will be made between the baseline level (M0) and the level observed at 3, 6 and 12 months for : - DAS28-ESR and DAS28-CRP - SDAI : - HAQ, SF-36 FLARE-RA quality of life score - PGA and EGA VAS - CDAI and DAS28-ESR LDA (low disease activity) - Proportion of patients achieving good or moderate European League Against Rheumatism (EULAR) therapeutic response (DS28-ESR) - Proportion of patients achieving ACR20, ACR50, and ACR70 responses - Rates of treatment persistence and at 3 and 12 months : - CDAI 2/ Tolerance observed at 3, 6 and 12 months - Proportion of patients presenting at least one side effect, according to NCI-CTCAE v4.0 scale: (Platelets, AST/ALT, Triglycerides, Neutropenia) - Rates of treatment withdrawals for intolerance - Rates of treatment withdrawals for intolerance requiring in-hospital care - Rate of rescue medication use authorized by the protocol and treatment dose 3/ Radiobiological criteria for a better understanding of pathophysiological phenomena: - changes in joint US-Doppler synovitis and Doppler hyperemia grade of the hands and wrists at 6 months - changes in Sharp score of hands, wrists and feets radiographs at 12 months - change in Vascular Endothelial Growth Factor (VEGF) levels at 3 and 6 months - changes in interleukin-6 serum levels at 6 months ;Timepoint(s) of evaluation of this end point: At inlusion , 3, 6 and 12 months	—

Measure

Time frame

Secondary end point(s): 1/ Secondary outcomes will assess treatment response. Comparisons will be made between the baseline level (M0) and the level observed at 3, 6 and 12 months for : - DAS28-ESR and DAS28-CRP - SDAI : - HAQ, SF-36 FLARE-RA quality of life score - PGA and EGA VAS - CDAI and DAS28-ESR LDA (low disease activity) - Proportion of patients achieving good or moderate European League Against Rheumatism (EULAR) therapeutic response (DS28-ESR) - Proportion of patients achieving ACR20, ACR50, and ACR70 responses - Rates of treatment persistence and at 3 and 12 months : - CDAI 2/ Tolerance observed at 3, 6 and 12 months - Proportion of patients presenting at least one side effect, according to NCI-CTCAE v4.0 scale: (Platelets, AST/ALT, Triglycerides, Neutropenia) - Rates of treatment withdrawals for intolerance - Rates of treatment withdrawals for intolerance requiring in-hospital care - Rate of rescue medication use authorized by the protocol and treatment dose 3/ Radiobiological criteria for a better understanding of pathophysiological phenomena: - changes in joint US-Doppler synovitis and Doppler hyperemia grade of the hands and wrists at 6 months - changes in Sharp score of hands, wrists and feets radiographs at 12 months - change in Vascular Endothelial Growth Factor (VEGF) levels at 3 and 6 months - changes in interleukin-6 serum levels at 6 months ;Timepoint(s) of evaluation of this end point: At inlusion , 3, 6 and 12 months

—

Countries

France

Contacts

Public ContactPromotion CRA

Groupement des Hôpitaux de l’Institut Catholique de Lille

vitagliano.jean-jacques@ghicl.net330320225751

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026